Assays and applications in warfarin metabolism: what we know, how we know it and what we need to know

Bibliography

• Ansell J, Hirsh J, Hylek E, Pharmacology and management of the vitamin k antagonists. Chest 2008;7(Suppl 6):160S-98S
   Web of Science ®Google Scholar
• Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007;167(13):1414-19
   PubMed Web of Science ®Google Scholar
• Kresge N, Simoni RD, Hill RL. Hemorrhagic sweet clover disease, dicumarol, and warfarin: the work of Karl Paul link. J Biol Chem 2005;280(8):e5
   PubMed Web of Science ®Google Scholar
• Overman R, Stahmann, MA, Studies on the hemorrhagic sweet clover disease: XIII. Anticoagulant activity and structure in the 4-hydroxycoumarin group. J Biol Chem 1944;153:5-24
   Google Scholar
• Gebauer M. Synthesis and structure-activity relationships of novel warfarin derivatives. Bioorg Med Chem 2007;15(6):2414-20
   PubMed Web of Science ®Google Scholar
• Breckenridge A, Orme M, Wesseling H, Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther 1974;15(4):424-30
   PubMed Web of Science ®Google Scholar
• O'Reilly RA. Vitamin K and the oral anticoagulant drugs. Annu Rev Med 1976;27(1):245-61
   PubMed Web of Science ®Google Scholar
• Breckenridge A. Oral anticoagulant drugs: pharmacokinetic aspects. Semin Hematol 1978;15(1):19-26
   PubMed Web of Science ®Google Scholar
• O'Reilly R. Warfarin metabolism and drug-drug interactions. In: Wessler S, Becker CG, Nemerson Y, editors, The new dimensions of warfarin prophylaxis: advances in experimental medicine and biology. NY, Plenum, New York; 1986. p. 205-12
   Google Scholar
• Toon S, Low LK, Gibaldi M, The warfarin-sulfinpyrazone interaction: stereochemical considerations. Clin Pharmacol Ther 1986;39(1):15-24
   PubMed Web of Science ®Google Scholar
• Lewis R, Trager WF. Warfarin metabolism in man: identification of metabolites in urine. J Clin Invest 1970;49(5):907-13
   PubMed Web of Science ®Google Scholar
• Lewis R, Trager WF, Robinson AJ, Chan KK. Warfarin metabolites: the anticoagulant activity and pharmacology of warfarin alcohols. J Lab Clin Med 1973;81(6):925-31
   PubMed Web of Science ®Google Scholar
• Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997;73:67-74
   PubMed Web of Science ®Google Scholar
• Rettie A, Korzekwa KR, Kunze KL, Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 1992;5(1):54-9
   PubMed Web of Science ®Google Scholar
• Miners J, Birkett, DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998;45:525-38
   PubMed Web of Science ®Google Scholar
• Takahashi H, Kashima T, Nomoto S, Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics 1998;8:365-73
   PubMedGoogle Scholar
• Brian WR, Sari M-A, Iwasaki M, Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae. Biochemistry 1990;29:11280-92
   PubMed Web of Science ®Google Scholar
• Ngui JS, Chen Q, Shou M, In vitro stimulation of warfarin metabolism by quinidine: increases in the formation of 4′- and 10-Hydroxywarfarin. Drug Metab Dispos 2001;29(6):877-86
   PubMed Web of Science ®Google Scholar
• Jones DR, Kim SY, Boysen G, Contribution of Three CYP3A Isoforms to Metabolism of R- and S-Warfarin. Drug Metab Lett 2010;4(4):213-9
   Google Scholar
• Kaminsky L, de Morais S, Faletto M, Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. Mol Pharmacol 1993;43(2):234-9
   PubMed Web of Science ®Google Scholar
• Rettie AE, Korzekwa KR, Kunze KL, Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 1992;5(1):54-9
   PubMed Web of Science ®Google Scholar
• Locatelli I, Kmetec V, Mrhar A, Determination of warfarin enantiomers and hydroxylated metabolites in human blood plasma by liquid chromatography with achiral and chiral separation. J Chromatogr B 2005;818(2):191-8
   PubMed Web of Science ®Google Scholar
• Miller GP, Jones DR, Sullivan SZ, Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans. Chem Res Toxicol 2009;22(7):1239-45
   PubMed Web of Science ®Google Scholar
• Zhang Z, Fasco MJ, Huang Z, Human cytochromes P450 1A1 and 1A2: R-warfarin as a probe. Drug Metab Dispos 1995;23:1339-45
   PubMed Web of Science ®Google Scholar
• Wienkers LC, Wurden CJ, Storch E, Formation of (R)-8-hydroxywarfarin in human liver microsomes: a new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metab Dispos 1996;24:610-14
   PubMed Web of Science ®Google Scholar
• Jones D, Boysen G, Miller GP. Novel dual-phase ultra performance liquid chromatography–tandem mass spectrometry assay for profiling enantiomeric hydroxywarfarins and warfarin in human plasma. J Chromatogr B. Doi: 10.1016/j.jchromb.2011.03.022. Available from: http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6X0P-52F6PGV-1&_user=1496715&_coverDate=03%2F21%2F2011&_alid=1708405284&_rdoc=1&_fmt=high&_orig=search&_origin=search&_zone=rslt_list_item&_cdi=7220&_sort=r&_st=13&_docanchor=&view=c&_ct=14&_acct=C000053083&_version=1&_urlVersion=0&_userid=1496715&md5=42753481053417e38566f5d5696c225e&searchtype=a
   Google Scholar
• Miller G. Warfarin therapy: how the less interesting half just got interesting. J Thromb Haemost 2010;8(12):2705-7
   PubMed Web of Science ®Google Scholar
• Lee S, Hwang HJ, Kim JM, CYP2C19 polymorphism in Korean patients on warfarin therapy. Arch Pharm Res 2007;30(3):344-9
   PubMed Web of Science ®Google Scholar
• Obayashi K, Nakamura K, Kawana J, VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin Pharmacol Ther 2006;80(2):169-78
   PubMed Web of Science ®Google Scholar
• Jorgensen AL, Al-Zubiedi S, Zhang JE, Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. Pharmacogenet Genomics 2009;19(10):800-12
   PubMed Web of Science ®Google Scholar
• Ritter JK. Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions. Chem Biol Interact 2000;129(1-2):171-93
   PubMed Web of Science ®Google Scholar
• Jansing R, Chao E, Kaminsky L. Phase II metabolism of warfarin in primary culture of adult rat hepatocytes. Mol Pharmacol 1992;41(1):209-15
   PubMed Web of Science ®Google Scholar
• Zielinska A, Lichti CF, Bratton S, Glucuronidation of monohydroxylated warfarin metabolites by human liver microsomes and human recombinant UDP-glucuronosyltransferases. J Pharmacol Exp Ther 2008;324(1):139-48
   PubMed Web of Science ®Google Scholar
• Miller GP, Lichti CF, Zielinska AK, Identification of hydroxywarfarin binding site in human UDP glucuronosyltransferase 1A10: phenylalanine90 is crucial for the glucuronidation of 6- and 7-Hydroxywarfarin but Not 8-Hydroxywarfarin 10.1124/dmd.108.022863. Drug Metab Dispos 2008;36(11):2211-18
   PubMed Web of Science ®Google Scholar
• Vesell E, Shively CA. Liquid chromatographic assay of warfarin: similarity of warfarin half-lives in human subjects. Science 1974;184(135):466-8
   PubMed Web of Science ®Google Scholar
• Kaiser D, Martin RS. GLC determination of warfarin in human plasma. J Pharm Sci 1974;63(10):1579-81
   PubMed Web of Science ®Google Scholar
• Midha K, McGilveray IJ, Cooper JK. GLC determination of plasma levels of warfarin. J Pharm Sci 1974;63(11):1725-9
   PubMed Web of Science ®Google Scholar
• Bjornsson T, Blaschke TF, Meffin PJ. High-pressure liquid chromatographic analysis of drugs in biological fluids I. Warfarin. J Pharm Sci 1977;66(1):142-4
   PubMed Web of Science ®Google Scholar
• Banfield C, Rowland M. Stereospecific high-performance liquid chromatographic analysis of warfarin in plasma. J Pharm Sci 1983;72(8):921-4
   PubMed Web of Science ®Google Scholar
• Banfield C, Rowland M. Stereospecific fluorescence high-performance liquid chromatographic analysis of warfarin and its metabolites in plasma and urine. J Pharm Sci 1984;73:1392-6
   PubMed Web of Science ®Google Scholar
• Chan E, McLachlan AJ, Pegg M, Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. Br J Clin Pharmacol 1994;37(6):563-9
   PubMed Web of Science ®Google Scholar
• Duffield A, Duffield PH, Birkett DJ, Plasma quantitation of warfarin and warfarin alcohol by gas chromatography chemical ionization mass spectrometry in patients on warfarin maintenance therapy. Biomed Mass Spectrom 1979;6(5):208-11
   PubMedGoogle Scholar
• Duffield P, Duffield AM, Kennedy M, Warfarin and warfarin-alcohol levels in anticoagulated patients. Aust NZ J Med 1979;9(5):534-7
   PubMedGoogle Scholar
• Bush E, Low LK, Trager WF. A sensitive and specific stable isotope assay for warfarin and its metabolites. Biomed Mass Spectrom 1983;10(7):395-8
   PubMedGoogle Scholar
• Takahashi H, Kashima T, Kimura S, Determination of unbound warfarin enantiomers in human plasma and 7-hydroxywarfarin in human urine by chiral stationary-phase liquid chromatography with ultraviolet or fluorescence and on-line circular dichroism detection. J Chromatogr B Biomed Sci Appl 1997;701(1):71-80
   PubMed Web of Science ®Google Scholar
• Fasco MJ, Vatsis KP, Kaminsky LS, Regioselective and stereoselective hydroxylation of R and S warfarin by different forms of purified cytochrome P-450 from rabbit liver. J Biol Chem 1978;253:7813-20
   PubMed Web of Science ®Google Scholar
• Fasco M, Cashin MJ, Kaminsky LS. A novel method for the quantitation of warfarin and its metabolites in plasma. J Liq Chromatogr 1979;2(4):565-75
   Web of Science ®Google Scholar
• Ufer M, Kammerer B, Kirchheiner J, Determination of phenprocoumon, warfarin and their monohydroxylated metabolites in human plasma and urine by liquid chromatography-mass spectrometry after solid-phase extraction. J Chromatogr B 2004;809(2):217-26
   PubMed Web of Science ®Google Scholar
• Spink DC, Aldous KM, Kaminsky LS. Analysis of oxidative warfarin metabolites by thermospray high-performance liquid chromatography/mass spectrometry. Anal Biochem 1989;177:307-13
   PubMed Web of Science ®Google Scholar
• Henne K, Gaedigk A, Gupta G, Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype. J Chromatogr B Biomed Sci Appl 1998;710:143-8
   PubMed Web of Science ®Google Scholar
• Zuo Z, Wo SK, Lo CMY, Simultaneous measurement of S-warfarin, R-warfarin, S-7-hydroxywarfarin and R-7-hydroxywarfarin in human plasma by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2010;52(2):305-10
   PubMed Web of Science ®Google Scholar
• Miura M, Okuyama S, Kato S, Simultaneous determination of warfarin and 7-hydroxywarfarin enantiomers by high-performance liquid chromatography with ultraviolet detection. Ther Drug Monit 2011;33(1):108-14
   PubMed Web of Science ®Google Scholar
• Lang D, Bocker R. Highly sensitive and specific high-performance liquid chromatographic analysis of 7-hydroxywarfarin, a marker for human cytochrome P-4502C9 activity. J Chromatogr 1995;672:305-9
   Web of Science ®Google Scholar
• Chu Y-Q, Wainer IW. The measurement of warfarin enantiomers in serum using coupled achiral/chiral, high-performance liquid chromatography (HPLC). Pharm Res 1988;5(10):680-3
   PubMed Web of Science ®Google Scholar
• Barker W, Hermodson M, Link K. The metabolism of 4-C14-warfarin sodium by rat. J Pharmacol Exp Ther 1970;171(2):307-13
   PubMed Web of Science ®Google Scholar
• Lewis R, Ilnicki LP, Carlstrom M. The assay of warfarin in plasma or stool. Biochem Med 1970;4(5):376-82
   PubMed Web of Science ®Google Scholar
• Lewis R, Trager WF, Chan KK, Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest 1974;53(6):1607-17
   PubMed Web of Science ®Google Scholar
• Zhang Z-Y, King BM, Wong YN. Quantitative liquid chromatography/mass spectrometry/mass spectrometry warfarin assay for in vitro cytochrome P450 studies. Anal Biochem 2001;298(1):40-9
   PubMed Web of Science ®Google Scholar
• Turpault S, Brian W, Van Horn R, Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. Br J Clin Pharmacol 2009;68(6):928-35
   PubMed Web of Science ®Google Scholar
• Kwon MJ, Kim HJ, Kim JW, Determination of plasma warfarin concentrations in Korean patients and its potential for clinical application. Korean J Lab Med 2009;29(6):515-23
   PubMed Web of Science ®Google Scholar
• Kulkarni UP, Swar BD, Karnad DR, A pilot study of the association of pharmacokinetic and pharmacodynamic parameters of warfarin with the dose in patients on long-term anticoagulation. Br J Clin Pharmacol 2008;65(5):787-90
   PubMed Web of Science ®Google Scholar
• Fasco MJ, Piper LJ, Kaminsky LS. Biochemical applications of a quantitative high-pressure liquid chromatographic assay of warfarin and its metabolites. J Chromatogr 1977;131:365-73
   PubMed Web of Science ®Google Scholar
• de Vries J, Kymber KA. Thermospray and particle beam liquid chromatographic-mass spectrometric analysis of coumarin anticoagulants. J Chromatogr 1991;562:31-8
   PubMed Web of Science ®Google Scholar
• Hermodson M. Biochemical studies on warfarin. University of Wisconsin, Madison, WI; 1968
   Google Scholar
• Howald W, Bush ED, Trager WF, A stable isotope assay for pseudoracemic warfarin from human plasma samples. Biomed Mass Spectrom 1980;7(1):35-40
   PubMedGoogle Scholar
• Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet(TM) systematic review and meta-analysis. Genet Med 2005;7(2):97-104
   PubMed Web of Science ®Google Scholar
• Steward DJ, Haining RL, Henne KR, Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 1997;7:361-7
   PubMedGoogle Scholar
• Takahashi H, Echizen H. Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Pharmacogenomics J 2003;3(4):202-14
   PubMed Web of Science ®Google Scholar
• Wadelius M, Chen LY, Eriksson N, Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 2007;121(1):23-34
   PubMed Web of Science ®Google Scholar
• Lenzini P, Wadelius M, Kimmel S, Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing. Clin Pharmacol Ther 2010;87(5):572-8
   PubMed Web of Science ®Google Scholar
• Jones D, Kim SY, Guderyon M, Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-Warfarin. Chem Res Toxicol 2010;23(5):939-45
   Google Scholar
• Rulcova A, Prokopova I, Krausova L, Stereoselective interactions of warfarin enantiomers with the pregnane X nuclear receptor in gene regulation of major drug-metabolizing cytochrome P450 enzymes. J Thromb Haemost 2010;8(12):2708-17
   PubMed Web of Science ®Google Scholar
• Miller G. Warfarin therapy: how the less interesting half just got interesting. J Thromb Haemost 2010;8(12):2705-7
   PubMed Web of Science ®Google Scholar
• Leeder J, Gaedigk A, Gupta G, Determinants of Warfarin S:R Ratio in Orthopedic Surgery (OS) Patients. Clin Pharmacol Ther 1999;65:194
   Web of Science ®Google Scholar
• Williams JA, Hyland R, Jones BC, Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 2004;32(11):1201-8
   PubMed Web of Science ®Google Scholar
• Frye RF. Probing the World of Cytochrome P450 Enzymes. Mol Interv 2004;4(3):157-62
   PubMed Web of Science ®Google Scholar
• Kaminsky LS. Warfarin as a probe of cytochromes P-450 function. Drug Metab Rev 1989;20:479-87
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens, and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-23
   PubMed Web of Science ®Google Scholar
• Kim J, Nafziger AN, Gaedigk A, Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe. J Clin Pharmacol 2001;41(7):715-22
   PubMed Web of Science ®Google Scholar
• Chainuvati S, Nafziger AN, Leeder JS, Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the [ldquo]Cooperstown 5+1 cocktail[rdquo][ast]. Clin Pharmacol Ther 2003;74(5):437-47
   PubMed Web of Science ®Google Scholar
• Shelepova T, Nafziger AN, Victory J, Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated cooperstown 5+1 Cocktail. J Clin Pharmacol 2005;45(12):1413-21
   PubMed Web of Science ®Google Scholar
• O'Sullivan TA, Wang JP, Unadkat JD, Disposition of drugs in cystic fibrosis. V. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced. Clin Pharmacol Ther 1993;54:323-8
   PubMed Web of Science ®Google Scholar
• Wang J, Unadkat JD, McNamara S, Disposition of drugs in cystic fibrosis. VI. In vivo activity of cytochrome P450 isoforms involved in the metabolism of (R)-warfarin (including P450 3A4) is not enhanced in cystic fibrosis. Clin Pharmacol Ther 1994;55(5):528-34
   PubMed Web of Science ®Google Scholar
• Jones D, Moran JH, Miller GP. Warfarin and UDP-glucuronosyltransferases: writing a new chapter of metabolism. Drug Metab Rev 2010;42(1):53-9
   Web of Science ®Google Scholar
• Harper T, Brassil P. Reaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates. AAPS J 2008;10(1):200-7
   PubMed Web of Science ®Google Scholar
• Lappin G, Kuhnz W, Jochemsen R, Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs[ast]. Clin Pharmacol Ther 2006;80(3):203-15
   PubMed Web of Science ®Google Scholar
• de Vries J, Volker U. Separation of the enantiomers of phenprocoumon and warfarin by high-performance liquid chromatography using a chiral stationary phase. Determination of the enantiomeric ratio of phenprocoumon in human plasma and urine. J Chromatogr 1989;493(1):149-56
   PubMed Web of Science ®Google Scholar
• Moser AC, Kingsbury C, Hage DS. Stability of warfarin solutions for drug-protein binding measurements: spectroscopic and chromatographic studies. J Pharm Biomed Anal 2006;41(4):1101-9
   PubMed Web of Science ®Google Scholar
• Takahashi H, Kashima T, Nomizo Y, Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther 1998;63:519-28
   PubMed Web of Science ®Google Scholar
• Guo Y, Weller P, Farrell E, In silico pharmacogenetics of warfarin metabolism. Nat Biotech 2006;24(5):531-6
   PubMed Web of Science ®Google Scholar
• Edelbroek P, van Kempen GM, Hessing TJ, de Wolff FA. Analysis of phenprocoumon and its hydroxylated and conjugated metabolites in human urine by high-performance liquid chromatography after solid-phase extraction. J Chromatogr 1990;530(2):347-58
   PubMed Web of Science ®Google Scholar
• Turpault S, Brian W, Van Horn R, Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. Br J Clin Pharmacol 2009;68(6):928-35
   PubMed Web of Science ®Google Scholar
• Malakova J, Pavek P, Svecova L, New high-performance liquid chromatography method for the determination of (R)-warfarin and (S)-warfarin using chiral separation on a glycopeptide-based stationary phase. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877(27):3226-30
   PubMed Web of Science ®Google Scholar